Acesso livre
Acesso livre

Alergia e Imunologia

Características clínicas da trombocitopenia e da trombose imunes induzidas por vacina.

12 Ago, 2021 | 12:21h

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis – New England Journal of Medicine

Comentário: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD

Conteúdos relacionados:

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

 

Comentário no Twitter

 

Diretriz | Diagnóstico e tratamento do lúpus cutâneo – Terapia, fatores de risco e outros tópicos.

12 Ago, 2021 | 12:11h

S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics – Journal of German Society of Dermatology

Breve revisão | Doenças bolhosas imunes.

12 Ago, 2021 | 11:54h

Immunobullous disease – Clinical Medicine Journal

Breve revisão | Avanços na dermatite atópica.

12 Ago, 2021 | 11:52h

Advances in atopic dermatitis – Clinical Medicine Journal

Estudo randomizado PRINCIPLE | Budesonida inalatória melhora o tempo de recuperação da COVID-19 em pessoas com alto risco de complicações na comunidade.

11 Ago, 2021 | 11:02h

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet

Comentário convidado: The use of inhaled corticosteroids in early-stage COVID-19

M-A | Mais de 50 efeitos de longo prazo da COVID-19.

11 Ago, 2021 | 10:57h

More than 50 long-term effects of COVID-19: a systematic review and meta-analysis – Scientific Reports

Conteúdos relacionados:

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Cohort study: Risk factors for long covid in previously hospitalized children.

Viewpoint: The road to addressing Long Covid.

Review: Long covid—mechanisms, risk factors, and management.

Review: Symptoms, complications and management of long COVID.

Long Covid: fatigue, post-exertional malaise, and cognitive dysfunction are the most common symptoms, according to an international survey.

Studies elucidate poorly understood long COVID.

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Long Covid: 39% of patients report persistent symptoms more than seven months after diagnosis of COVID-19 in an outpatient setting.

[Preprint] Long Covid: Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people.

Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms.

Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.

[Preprint] Long Covid: Third of people infected have long term symptoms.

Opinion | Causation or confounding: why controls are critical for characterizing long COVID – “Many of the self-reported symptoms, such as intermittent headaches or tiredness, are nonspecific and prevalent in the general population”.

Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.

Perspective | The four most urgent questions about long COVID.

Systematic review: Frequency, signs and symptoms, and criteria adopted for long COVID-19.

Report: 376,000 people in UK have had long Covid symptoms for at least a year.

Systematic review of 45 studies including 9751 participants, most of which were hospitalized, found 73% had at least 1 persistent symptom for weeks after Covid-19.

COVID Morbidity – The emerging burden of long COVID is significant, and needs to be considered when evaluating the risk vs. benefit of pandemic measures.

One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively

Population-based cohort study: Non-hospitalized COVID-19 patients have low-risk of serious long-term effects, but visits to general practitioners and outpatient hospital visits are increased.

One third of patients hospitalized with COVID-19 have lung changes after a year

Long Covid: Largest post-acute COVID-19 study to date examined the health outcomes in more than 73,000 people who’d had COVID-19 and were not hospitalized

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Perspective | They Tested Negative for Covid. Still, They Have Long Covid Symptoms.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions

Cohort study: One in ten have long-term effects 8 months following mild COVID-19

Long Covid Implications for the workplace

Long Covid in the UK – More than a million affected in February, survey suggests

Covid-19: Middle aged women face greater risk of debilitating long term symptoms

Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”

Opinion | We need to start thinking more critically — and speaking more cautiously — about long Covid

Review | Post-acute COVID-19 syndrome

Long Covid | Four-month clinical status of a cohort of patients after hospitalization for COVID-19

Perspective | Long Covid isn’t as unique as we thought

Attributes and predictors of long COVID

WHO Report: Preparing for Long COVID 2021

Long Covid: Sequelae in adults at 6 Months after COVID-19 infection

How many people get ‘long COVID’ – and who is most at risk?

Long Covid: Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge

Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline

Patients, clinicians seek answers to the mystery of ‘Long COVID’

Long Covid: 6-month consequences of COVID-19 in patients discharged from hospital

[Preprint] Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact

NICE Guideline: Managing the long-term effects of COVID-19

 

Comentário no Twitter

 

[Preprint] Estudo randomizado fase 1/2 | Uma dose de reforço é imunogênica e será necessária para idosos que completaram o esquema de duas doses com CoronaVac.

10 Ago, 2021 | 12:44h

A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – medRxiv

 

Comentário no Twitter

 

Dermatoses autoimunes bolhosas: características clínicas, avaliação diagnóstica e opções de tratamento.

10 Ago, 2021 | 12:18h

Bullous Autoimmune Dermatoses – Deutsches Ärzteblatt International

Estudo randomizado | Segurança e imunogenicidade de esquemas de segunda dose heterólogos vs. homólogos de vacinas contra COVID-19 com vetor adenoviral vs. de mRNA.

9 Ago, 2021 | 11:40h

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial – The Lancet

Comentário convidado: Optimising SARS-CoV-2 vaccination schedules – The Lancet

Conteúdo relacionado: Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (vários artigos sobre o tema)

 

Comentário no Twitter

 

Estudo do CDC mostrou um risco reduzido de reinfecção por SARS-CoV-2 após vacinação contra Covid-19.

9 Ago, 2021 | 11:37h

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 – CDC Morbidity and Mortality Weekly Report

 

Comentários no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.